These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 3625258)

  • 61. Immunotherapy with anti-G
    Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
    Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8.
    Bergman I; Barmada MA; Heller G; Griffin JA; Cheung NK
    Int J Cancer; 1999 Aug; 82(4):538-48. PubMed ID: 10404068
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.
    Kramer K; Humm JL; Souweidane MM; Zanzonico PB; Dunkel IJ; Gerald WL; Khakoo Y; Yeh SD; Yeung HW; Finn RD; Wolden SL; Larson SM; Cheung NK
    J Clin Oncol; 2007 Dec; 25(34):5465-70. PubMed ID: 18048828
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
    Saleh MN; Khazaeli MB; Wheeler RH; Allen L; Tilden AB; Grizzle W; Reisfeld RA; Yu AL; Gillies SD; LoBuglio AF
    Hum Antibodies Hybridomas; 1992 Jan; 3(1):19-24. PubMed ID: 1576319
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment and outcome of adult-onset neuroblastoma.
    Suzuki M; Kushner BH; Kramer K; Basu EM; Roberts SS; Hammond WJ; LaQuaglia MP; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2018 Sep; 143(5):1249-1258. PubMed ID: 29574715
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
    Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
    J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
    Handgretinger R; Anderson K; Lang P; Dopfer R; Klingebiel T; Schrappe M; Reuland P; Gillies SD; Reisfeld RA; Neithammer D
    Eur J Cancer; 1995; 31A(2):261-7. PubMed ID: 7718335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Human monoclonal antibody to tumor-associated ganglioside GD2.
    Katano M; Saxton RE; Irie RF
    J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
    Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB
    Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122
    [TBL] [Abstract][Full Text] [Related]  

  • 70. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.
    Bajorin DF; Chapman PB; Wong GY; Cody BV; Cordon-Cardo C; Dantes L; Templeton MA; Scheinberg D; Oettgen HF; Houghton AN
    Melanoma Res; 1992 Dec; 2(5-6):355-62. PubMed ID: 1292783
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
    Ohta S; Igarashi S; Honda A; Sato S; Hanai N
    Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a phase II trial.
    Cheung NK; Burch L; Kushner BH; Munn DH
    Prog Clin Biol Res; 1991; 366():395-400. PubMed ID: 2068154
    [No Abstract]   [Full Text] [Related]  

  • 75. Immunological response to intrathecal and systemic treatment with ganglioside antibody R-24 in patients with malignant melanoma.
    Dippold W; Bernhard H; Meyer zum Büschenfelde KH
    Eur J Cancer; 1994; 30A(2):137-44. PubMed ID: 8155384
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
    Kusano A; Ohta S; Shitara K; Hanai N
    Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats.
    Bergman I; Pohl CR; Venkataramanan R; Burckart GJ; Stabin M; Barmada MA; Griffin JA; Cheung NK
    J Immunother; 1999 Mar; 22(2):114-23. PubMed ID: 10093036
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
    Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
    Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
    Irie RF; Morton DL
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8694-8. PubMed ID: 3464977
    [TBL] [Abstract][Full Text] [Related]  

  • 80. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors.
    Fonti R; Cheung NK; Bridger GJ; Guo HF; Abrams MJ; Larson SM
    Nucl Med Biol; 1999 Aug; 26(6):681-6. PubMed ID: 10587107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.